3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
7
Genitourinary
3
Sarcoma
2
Gastrointestinal
2
Breast
2
Thoracic
1
Other hematologic neoplasm
1
Lymphoid
1
Head & Neck
1
CNS
1
Conditions
Lymphoma, Non-Hodgkin
2
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Neuroblastoma
1
Neoplasms
1
Melanoma
1
Medulloblastoma
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Interventions
pembrolizumab
14
Nivolumab
9
Specimen Handling
4
Magnetic Resonance Spectroscopy
4
fludarabine
3
atezolizumab
3
Ipilimumab
3
Drug Therapy
3
Cyclophosphamide
3
epacadostat
2
entrectinib
2
durvalumab
2
X-Rays
2
Sirolimus
2
Radiotherapy
2
Radiation
2
Methods
2
Interleukin-2
2
Injections
2
CTLA-4 Antigen
2
Blood Specimen Collection
2
Biopsy
2
zimberelimab
1
vocimagene amiretrorepvec
1
varlilumab
1
utomilumab
1
ulixertinib
1
tremelimumab
1
trastuzumab biosimilar HLX02
1
trametinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
bempegaldesleukin
×
Lymphoid
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts